193 related articles for article (PubMed ID: 33582427)
1. Targeted therapy for treatment of patients with classical hairy cell leukemia.
Moore JE; Delibert K; Baran AM; Evans AG; Liesveld JL; Zent CS
Leuk Res; 2021 Mar; 102():106522. PubMed ID: 33582427
[TBL] [Abstract][Full Text] [Related]
2. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.
Tiacci E; De Carolis L; Simonetti E; Capponi M; Ambrosetti A; Lucia E; Antolino A; Pulsoni A; Ferrari S; Zinzani PL; Ascani S; Perriello VM; Rigacci L; Gaidano G; Della Seta R; Frattarelli N; Falcucci P; Foà R; Visani G; Zaja F; Falini B
N Engl J Med; 2021 May; 384(19):1810-1823. PubMed ID: 33979489
[TBL] [Abstract][Full Text] [Related]
3. Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience.
Yiğit Kaya S; Mutlu YG; Malkan ÜY; Mehtap Ö; Keklik Karadağ F; Korkmaz G; Elverdi T; Saydam G; Özet G; Ar MC; Melek E; Maral S; Kaynar L; Sevindik ÖG
Leuk Res; 2024 May; 140():107495. PubMed ID: 38599153
[TBL] [Abstract][Full Text] [Related]
4. Inhibitor of BRAF
Smirnova SY; Al-Radi LS; Moiseeva TN; Gemdzhian EG; Yakutik IA; Julhakyan HL; Novikov VA; Galstyan GM; Sudarikov AB
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):427-430. PubMed ID: 33811006
[TBL] [Abstract][Full Text] [Related]
5. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence.
Else M; Dearden CE; Matutes E; Forconi F; Lauria F; Ahmad H; Kelly S; Liyanage A; Ratnayake V; Shankari J; Whalley I; Catovsky D
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():75-8. PubMed ID: 21504288
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.
Else M; Dearden CE; Matutes E; Garcia-Talavera J; Rohatiner AZ; Johnson SA; O'Connor NT; Haynes A; Osuji N; Forconi F; Lauria F; Catovsky D
Br J Haematol; 2009 Jun; 145(6):733-40. PubMed ID: 19344416
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine and rituximab for relapsed or refractory hairy cell leukemia.
Gerrie AS; Zypchen LN; Connors JM
Blood; 2012 Mar; 119(9):1988-91. PubMed ID: 22223825
[TBL] [Abstract][Full Text] [Related]
8. Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC).
López Rubio M; Da Silva C; Loscertales J; Seri C; Baltasar P; Colado E; Pérez Fernández I; Osma M; Gomis F; González M; Jarque I; Vargas M; Monzó E; Monteagudo D; Orts MI; Pardal E; Carbonell F; Perez Calvo C; Garcia-Marco JA
Leuk Lymphoma; 2014 May; 55(5):1007-12. PubMed ID: 23885799
[TBL] [Abstract][Full Text] [Related]
9. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia.
Else M; Osuji N; Forconi F; Dearden C; Del Giudice I; Matutes E; Wotherspoon A; Lauria F; Catovsky D
Cancer; 2007 Nov; 110(10):2240-7. PubMed ID: 17886250
[TBL] [Abstract][Full Text] [Related]
10. How I manage patients with hairy cell leukaemia.
Thompson PA; Ravandi F
Br J Haematol; 2017 May; 177(4):543-556. PubMed ID: 28146266
[TBL] [Abstract][Full Text] [Related]
11. Current Therapy and New Directions in the Treatment of Hairy Cell Leukemia: A Review.
Sarvaria A; Topp Z; Saven A
JAMA Oncol; 2016 Jan; 2(1):123-9. PubMed ID: 26513168
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up after purine analogue therapy in hairy cell leukaemia.
Else M; Dearden CE; Catovsky D
Best Pract Res Clin Haematol; 2015 Dec; 28(4):217-29. PubMed ID: 26614900
[TBL] [Abstract][Full Text] [Related]
13. Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.
Chihara D; Arons E; Stetler-Stevenson M; Yuan CM; Wang HW; Zhou H; Raffeld M; Xi L; Steinberg SM; Feurtado J; James L; Wilson W; Braylan RC; Calvo KR; Maric I; Dulau-Florea A; Kreitman RJ
J Clin Oncol; 2020 May; 38(14):1527-1538. PubMed ID: 32109194
[TBL] [Abstract][Full Text] [Related]
14. Response to the Therapy in Hairy Cell Leukemia: Systematic Review and Meta-Analysis.
Andrasiak I; Rybka J; Wrobel T
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):392-399.e3. PubMed ID: 29685423
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous leukocytoclastic vasculitis at diagnosis of hairy cell leukemia successfully treated with vemurafenib and rituximab.
Robak E; Jesionek-Kupnicka D; Iskierka-Jazdzewska E; Janus A; Robak T
Leuk Res; 2021 May; 104():106571. PubMed ID: 33831657
[No Abstract] [Full Text] [Related]
16. Hairy Cell Leukaemia.
Cross M; Dearden C
Curr Oncol Rep; 2020 Apr; 22(5):42. PubMed ID: 32297104
[TBL] [Abstract][Full Text] [Related]
17. Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox.
Robak T; Janus A; Jamroziak K; Tiacci E; Kreitman RJ
J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34202156
[TBL] [Abstract][Full Text] [Related]
18. Chemoimmunotherapy for hairy cell leukemia.
Ravandi F
Best Pract Res Clin Haematol; 2015 Dec; 28(4):230-5. PubMed ID: 26614901
[TBL] [Abstract][Full Text] [Related]
19. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.
Chihara D; Kantarjian H; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Poku R; Jain P; Thompson P; Brandt M; Luthra R; Burger J; Keating M; Ravandi F
Br J Haematol; 2016 Sep; 174(5):760-6. PubMed ID: 27301277
[TBL] [Abstract][Full Text] [Related]
20. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]